1500P - Response to chemotherapy in solitary fibrous tumor

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anti-Cancer Agents & Biologic Therapy
Soft Tissue Sarcomas
Presenter Silvia Stacchiotti
Authors S. Stacchiotti1, M. Libertini2, E. Palassini3, T. Negri4, S. Fatigoni5, P. Poletti6, B. Vincenzi7, A.P. Dei Tos8, S. Pilotti4, P.G. Casali3
  • 1Oncologia Medica 2, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2Clinica Oncologica, Fondazione IRCCS Istituto Nazionale Tumori, 20133 - Milan/IT
  • 3Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 4Pathology And Molecular Biology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 5Oncologia Medica, Azienda Ospedaliera Sta Maria, IT-05100 - Terni/IT
  • 6Ospedali Riuniti di Bergamo, IT-24100 - Bergamo/IT
  • 7University Campus Bio-Medico, Roma/IT
  • 8Pathology, General Hospital of Treviso, IT-31100 - Treviso/IT

Abstract

Background

To report on anthracycline-based chemotherapy in a retrospective case series analysis of 45 solitary fibrous tumor (SFT) patients treated within the Italian Rare Cancer Network (RTR).

Methods

We retrospectively reviewed all SFT treated with chemotherapy at our Institution or within RTR since 2002, focusing on anthracyclines (i.e. doxorubicin or epirubicin), administered alone or in combination with ifosfamide. Responses to ifosfamide as a single agent were also evaluated. Pathologic diagnosis was centrally reviewed in all cases, by distinguishing typical, malignant (MSFT) and dedifferentiated (DSFT) SFT subtypes.

Results

Among 45 pts with SFT treated with chemotherapy, we could select 31 patients (M/F: 14/17 – mean age: 62 years - locally advanced/metastatic/adjuvant: 13/17/1 - front-line/ further line = 25/5; typical/MSFT/DSFT = 0/17/13) who received anthracycline-based chemotherapy (single agent in 6, combined with ifosfamide in 24). 28 pts are evaluable for response (adjuvant = 1; too early = 1; other = 1). Overall, best response according to RECIST was: partial response (PR) = 6 (21%), stable disease (SD) = 7, progressive disease (PD) = 15 cases. Responses were confirmed after 3 months. In 2 pts with SD, a minor dimensional response was detected. Median PFS was 4 (range 2-15) months, with 20% of patients being progression-free at 6 months. PR were found in 1/16 (6%) MSFT e 5/12 (41%) DSFT. 17 pts received high-dose prolonged-infusion ifosfamide (front-line/further line = 15/2; typical/MSFT/DSFT/not assessable = 0/11/3/3 with 2 PR (both MSFT), 4 SD, 11 PD.

Conclusions

Anthracycline-base chemotherapy is active in a proportion of SFT pts. However, a high response rate was observed in DFST. Comparatively, ifosfamide as a single agent has low activity.

Disclosure

S. Stacchiotti: Pfizer: research grant for studies in which my institution is involved; honoraria.

M. Libertini: Pfizer: research grant for studies in which my institution is involved;.

E. Palassini: Pfizer: research grant for studies in which my institution is involved;.

B. Vincenzi: Pfizer: honoraria.

A.P. Dei Tos: Pfizer: honoraria.

P.G. Casali: Pfizer: research grant for studies in which my institution is involved; honoraria; advisory (compensated).

All other authors have declared no conflicts of interest.